The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells

Biochemical and Biophysical Research Communications

Volumn 420, Issue 4, 2012, Pages 775-781

  Aoyama, Sayuri ^a   Nakano, Hiroko ^a   Danbara, Mikio ^a   Higashihara, Masaaki ^a   Harigae, Hideo ^b   Takahashi, Shinichiro ^a  

^a KITASATO UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2 Aza 5' deoxycytidine; Apoptosis; Erythroid differentiation; K562; PU.1

Indexed keywords

2 AZA 5' DEOXYCYTIDINE; DEOXYCYTIDINE; GLYCOSYLATED HEMOGLOBIN; RNA; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN K 562; CONTROLLED STUDY; DRUG EFFECT; ERYTHROID CELL; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; AZACITIDINE; BETA-GLOBINS; CELL DIFFERENTIATION; CYCLIN B1; DNA DAMAGE; ERYTHROID CELLS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; K562 CELLS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; TRANSGENES;

EID: 84859817127     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.071     Document Type: Article

References (38)

1. Chen H.M., Zhang P., Voso M.T., Hohaus S., Gonzalez D.A., Glass C.K., Zhang D.E., Tenen D.G. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood 1995, 85:2918-2928.
2. Back J., Dierich A., Bronn C., Kastner P., Chan S. PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood 2004, 103:3615-3623.
3. R. Pop, J.R. Shearstone, Q. Shen, Y. Liu, K. Hallstrom, M. Koulnis, J. Gribnau, M. Socolovsky, A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase progression, PLoS Biol. 8 (2010).
4. Rao G., Rekhtman N., Cheng G., Krasikov T., Skoultchi A.I. Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene 1997, 14:123-131.
5. Wontakal S.N., Guo X., Will B., Shi M., Raha D., Mahajan M.C., Weissman S., Snyder M., Steidl U., Zheng D., Skoultchi A.I. A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1. PLoS Genet. 2011, 7:e1001392.
6. Fernandez-Nestosa M.J., Hernandez P., Schvartzman J.B., Krimer D.B. PU.1 is dispensable to block erythroid differentiation in Friend erythroleukemia cells. Leuk. Res. 2008, 32:121-130.
7. Leone G., Teofili L., Voso M.T., Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002, 87:1324-1341.
8. Issa J.P. Epigenetic changes in the myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 2010, 24:317-330.
9. de Vos D., van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann. Hematol. 2005, 84(Suppl. 1):3-8.
10. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., Larson R.A. Further analysis of trials with azacytidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006, 24:3895-3903.
11. Ravandi F., Burnett A.K., Agura E.D., Kantarjian H.M. Progress in the treatment of acute myeloid leukemia. Cancer 2007, 110:1900-1910.
12. Hackanson B., Robbel C., Wijermans P., Lubbert M. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann. Hematol. 2005, 84(Suppl. 1):32-38.
13. Rosenbauer F., Wagner K., Kutok J.L., Iwasaki H., Le Beau M.M., Okuno Y., Akashi K., Fiering S., Tenen D.G. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat. Genet. 2004, 36:624-630. (Epub 2004 May 2016).
14. Pettersson M., Sundstrom C., Nilsson K., Larsson L.G. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood 1995, 86:2747-2753.
15. Huh H.J., Chae S.L., Lee M., Hong K.S., Mun Y.C., Seong C.M., Chung W.S., Huh J.W. CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome. Int. J. Lab. Hematol. 2009, 31:344-351.
16. Imoto A., Okada M., Okazaki T., Kitasato H., Harigae H., Takahashi S. Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J. Biol. Chem. 2010, 285:10300-10309.
17. Iseki Y., Imoto A., Okazaki T., Harigae H., Takahashi S. Identification of annexin 1 as a PU.1 target gene in leukemia cells. Leuk. Res. 2009, 33:1658-1663.
18. Iseki Y., Nakahara M., Kubo M., Obata F., Harigae H., Takahashi S. Correlation of PU.1 and signal regulatory protein alpha1 expression in PU.1 transgenic K562 cells. Int. J. Mol. Med. 2012, 29:319-323.
19. Takahashi S., Harigae H., Kameoka J., Sasaki T., Kaku M. AML1B transcriptional repressor function is impaired by the Flt3 internal tandem duplication. Br. J. Haematol. 2005, 130:428-436.
20. van Groeningen C.J., Leyva A., O'Brien A.M., Gall H.E., Pinedo H.M. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986, 46:4831-4836.
21. Porter L.A., Donoghue D.J. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res. 2003, 5:335-347.
22. Redon C., Pilch D., Rogakou E., Sedelnikova O., Newrock K., Bonner W. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 2002, 12:162-169.
23. Schnekenburger M., Grandjenette C., Ghelfi J., Karius T., Foliguet B., Dicato M., Diederich M. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem. Pharmacol. 2011, 81:364-378.
24. Lubbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., Andre M., Ferrant A. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br. J. Haematol. 2001, 114:349-357.
25. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., Ellerton J., Larson R.A., Schiffer C.A., Holland J.F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20:2429-2440.
26. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Faderl S., Issa J.P., Garcia-Manero G., Rios M.B., Shan J., Andreeff M., Keating M., Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003, 98:522-528.
27. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
28. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 2008, 28:752-771.
29. Constantinides P.G., Jones P.A., Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 1977, 267:364-366.
30. Creusot F., Acs G., Christman J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J. Biol. Chem. 1982, 257:2041-2048.
31. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O.A., Di Fiore P.P. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984, 64:922-929.
32. Valdez B.C., Li Y., Murray D., Corn P., Champlin R.E., Andersson B.S. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk. Res. 2010, 34:364-372.
33. Ning B., Liu G., Liu Y., Su X., Anderson G.J., Zheng X., Chang Y., Guo M., Liu Y., Zhao Y., Nie G. 5-Aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. J. Biol. Chem. 2011, 286:37196-37206.
34. Wu K.J., Polack A., Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999, 283:676-679.
35. Kihara-Negishi F., Yamamoto H., Suzuki M., Yamada T., Sakurai T., Tamura T., Oikawa T. In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression. Oncogene 2001, 20:6039-6047.
36. Yamada T., Kondoh N., Matsumoto M., Yoshida M., Maekawa A., Oikawa T. Overexpression of PU.1 induces growth and differentiation inhibition and apoptotic cell death in murine erythroleukemia cells. Blood 1997, 89:1383-1393.
37. Donze D., Townes T.M., Bieker J.J. Role of erythroid Kruppel-like factor in human gamma- to beta-globin gene switching. J. Biol. Chem. 1995, 270:1955-1959.
38. Wall L., Destroismaisons N., Delvoye N., Guy L.G. CAAT/enhancer-binding proteins are involved in beta-globin gene expression and are differentially expressed in murine erythroleukemia and K562 cells. J. Biol. Chem. 1996, 271:16477-16484.